Literature DB >> 12127152

Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells.

María Antonia Baltrons1, Carlos E Pedraza, Michael T Heneka, Agustina García.   

Abstract

In astroglial cells beta-amyloid peptides (betaA) induce a reactive phenotype and increase expression of NO synthase. Here we show that treatment of rat brain astrocytes with betaA decreases their capacity to accumulate cyclic GMP (cGMP) in response to NO as a result of a decreased expression of soluble guanylyl cyclase (sGC) at the protein and mRNA levels. Potentiation of betaA-induced NO formation by interferon-gamma did not result in a larger decrease in cGMP formation and inhibition of NO synthase failed to reverse down-regulation of sGC, indicating that NO is not involved. The betaA effect was prevented by the protein synthesis inhibitor cycloheximide. Intracerebral betaA injection also decreased sGC beta1 subunit mRNA levels in adult rat hippocampus and cerebellum. A loss of sGC in reactive astrocytes surrounding beta-amyloid plaques could be a mechanism to prevent excess signalling via cGMP at sites of high NO production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127152     DOI: 10.1006/nbdi.2002.0492

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  14 in total

Review 1.  Regulation and function of cyclic GMP-mediated pathways in glial cells.

Authors:  María Antonia Baltrons; Mariela Susana Borán; Paula Pifarré; Agustina García
Journal:  Neurochem Res       Date:  2008-04-01       Impact factor: 3.996

2.  Glucagon-like peptide-2 (GLP-2) modulates the cGMP signalling pathway by regulating the expression of the soluble guanylyl cyclase receptor subunits in cultured rat astrocytes.

Authors:  Esther Velázquez; Enrique Blázquez; Juan Miguel Ruiz-Albusac
Journal:  Mol Neurobiol       Date:  2012-07-18       Impact factor: 5.590

3.  Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory.

Authors:  Agostino Palmeri; Roberta Ricciarelli; Walter Gulisano; Daniela Rivera; Claudia Rebosio; Elisa Calcagno; Maria Rosaria Tropea; Silvia Conti; Utpal Das; Subhojit Roy; Maria Adelaide Pronzato; Ottavio Arancio; Ernesto Fedele; Daniela Puzzo
Journal:  J Neurosci       Date:  2017-06-16       Impact factor: 6.167

Review 4.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

5.  Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.

Authors:  Neema S Patel; Jennifer Klett; Katy Pilarzyk; Dong Ik Lee; David Kass; Frank S Menniti; Michy P Kelly
Journal:  Neurobiol Aging       Date:  2018-02-05       Impact factor: 4.673

Review 6.  Synaptic therapy in Alzheimer's disease: a CREB-centric approach.

Authors:  Andrew F Teich; Russell E Nicholls; Daniela Puzzo; Jole Fiorito; Rosa Purgatorio; Mauro Fa'; Ottavio Arancio
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 7.  Pharmacokinetics and pharmacodynamics of nitric oxide mimetic agents.

Authors:  Austin Horton; Isaac T Schiefer
Journal:  Nitric Oxide       Date:  2019-01-11       Impact factor: 4.427

Review 8.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

9.  Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner.

Authors:  Thomas W Miller; Jeff S Isenberg; Hubert B Shih; Yichen Wang; David D Roberts
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

10.  Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderly.

Authors:  Ashley C Torregrossa; Mayank Aranke; Nathan S Bryan
Journal:  J Geriatr Cardiol       Date:  2011-12       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.